Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • NPI Medicare & Medicaid
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.28
    OpenPayerPolicy UpdatesImmunology/Rheumatologyallcareadvantage belimumab Prior Auth Coverage | O…
    Ask Trek AI about this page
    CurrentallcareadvantagePolicy 103.1

    Belimumab (Benlysta) prior authorization — coverage criteria for SLE and lupus nephritis

    Customize your policy alerts

    Sign up for allcareadvantage Policy 103.1 alerts

    Get alerted when Policy 103.1 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines prior authorization criteria, approval length, quantity limits, and clinical requirements for coverage of belimumab (Benlysta) for members with systemic lupus erythematosus (SLE) or lupus nephritis (LN). Applies to AllCare Advantage prior authorization review for prescribers and reviewers.

    Policy Summary
    Payerallcareadvantage
    PolicyBelimumab (Benlysta) prior authorization — coverage criteria for SLE and lupus nephritis
    Policy CodePolicy 103.1
    Change TypeNo material changes
    Effective DateJun 1, 2021
    Last ReviewApr 26, 2021
    Next Review DateJun 17, 2023
    Key ActionObtain prior authorization and document prescriber specialty, diagnosis, age, baseline activity assessment or recent renal biopsy, current standard therapy, and absence of excluded concurrent biologics.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    Up to 6 monthsApproval length
    ≥5 yrsMin age (SLE)
    >18 yrsLN renewal age
    400 mg weekly

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Quantity limit (LN)

    Coverage Criteria for Belimumab

    Initial and Renewal Criteria

    Covered when ALL of the following are met (staged decision tree):

    Initial approval cluster

    • Diagnosis: Patient has active autoantibody-positive SLE with baseline assessment of SLE disease activity using a validated functional assessment tool OR has active lupus nephritis with renal biopsy within the previous 6 months to 2 years
    • Provider: Prescription written by (or in consultation with) a rheumatologist or nephrologist
    • Age: For SLE: patient age >5 years; for certain lupus nephritis pathways: patient age >18 years referenced
    • Concurrent therapy: Patient is currently receiving standard of care treatment for SLE or lupus nephritis and documentation member will continue receiving standard therapy
    • Concomitant biologics/CYC: Patient is not currently on other biologic therapy or intravenous cyclophosphamide
    • CNS lupus: No documentation of severe active central nervous system lupus
    Renewal for SLE: For SLE renewal: member has been evaluated by a rheumatologist or nephrologist within the prior 6 months (or is scheduled for evaluation within 3 months) AND SLE disease activity has improved as assessed by a validated functional assessment tool
    Renewal for LN: For lupus nephritis renewal: member age >18 years AND documentation or physician attestation of at least 50% reduction in proteinuria after 6 months of therapy AND continued receipt of standard therapy

    Belimumab is not recommended and requests should be denied when there is documentation of severe active central nervous system (CNS) lupus. The clinical rationale in the policy specifies that belimumab has not been evaluated in this population and is contraindicated in combination with other biologic products; therefore, requests that would involve concomitant use of another biologic agent should be denied. Additionally, monitor and assess for depression and suicidality before and during treatment, as these events have been reported in trials of belimumab.

    Operational denial criteria include the following scenarios: the prescription is not written by or in consultation with a rheumatologist or nephrologist (deny); the member does not meet the age thresholds (age <= 5 years for SLE or, where specified for LN renewal, age <= 18 years) (deny); baseline diagnostics or activity assessments are missing as required (for SLE, no baseline validated functional assessment tool; for LN, no renal biopsy within the prior 6 months to 2 years) (deny); the patient is currently on other biologic therapy or receiving intravenous cyclophosphamide (deny); or the patient is not currently receiving standard of care therapy for SLE or LN (deny).

    Covered Agents and Coding

    Covered agentsmixedCovered
    belimumabBenlysta (BLyS-specific inhibitor) — drug included in criteria
    Proteinuria response for LN renewal
    Numeric threshold≥ 50% reduction in proteinuria after 6 months of therapy
    Applicable populationMembers being treated for lupus nephritis (LN) seeking renewal
    Documentation requiredPhysician attestation or documentation demonstrating the ≥50% reduction in proteinuria after 6 months
    Age considerationRenewal criteria reference: member age >18 years

    Provider Actions and Documentation Requirements

    Prior Authorization

    Prior authorization required; contingent on staged criteria

    Prior authorization is required for belimumab; approval is contingent on meeting the staged decision tree criteria including prescriber specialty, diagnosis (active autoantibody‑positive SLE with baseline assessment OR active lupus nephritis with recent renal biopsy), age thresholds, receipt of standard therapy, no concurrent biologic or IV cyclophosphamide, and absence of severe active CNS lupus.

    • Approval is granted only if all applicable criteria in the staged decision tree are met (see Criteria #2–#8 and #10).
    • Approval length: up to 6 months.
    Step Therapy

    Must be receiving and continue standard-of-care therapy

    The patient must be currently receiving standard-of-care treatment for SLE or lupus nephritis as a prerequisite for approval; lack of ongoing standard therapy leads to denial.

    • Criteria #6 requires the patient to be currently receiving standard of care treatment for SLE; Criteria #10 for renewal requires documentation the member will continue receiving standard therapy.

    Standard Therapy and Definitions

    Standard therapy (concomitant treatments)
    Standard therapy expectationPatient is currently receiving and will continue to receive standard-of-care treatment for SLE or LN
    Examples noted in policy contextConcomitant conventional treatments are referenced as the ongoing standard-of-care agents for SLE or LN (policy does not list specific agents in criteria text)
    Prescriber roleApproval contingent on documentation that patient is receiving standard therapy as part of prior authorization requirements
    Exclusion if absentRequests may be denied if standard therapy is not being provided or continued

    Background

    Belimumab (Benlysta) is a B-lymphocyte stimulator (BLyS)–specific inhibitor approved for use in patients with active, autoantibody-positive systemic lupus erythematosus (SLE) aged 5 years and older receiving standard therapy, and for adults with active lupus nephritis receiving standard therapy. The policy notes reported risks of depression and suicidality, which should be assessed prior to and monitored during treatment.

    Revision History

    2021-06-01policy_effective

    Policy originated (Date of origin) for belimumab prior authorization (Policy 103.1).

    2021-04-26policy_revision

    Policy last revised (administrative record shows last revised on 2021-04-26).

    2021-06-17last_review

    Policy last reviewed on 2021-06-17; review recorded in the policy header and review metadata.

    Policy Summary
    Payerallcareadvantage
    PolicyBelimumab (Benlysta) prior authorization — coverage criteria for SLE and lupus nephritis
    Policy CodePolicy 103.1
    Change TypeNo material changes
    Effective DateJun 1, 2021
    Last ReviewApr 26, 2021
    Next Review DateJun 17, 2023
    Key ActionObtain prior authorization and document prescriber specialty, diagnosis, age, baseline activity assessment or recent renal biopsy, current standard therapy, and absence of excluded concurrent biologics.
    SourceLink
    On This Page
    Coverage Criteria for BelimumabCovered Agents and CodingProvider Actions and Documentation RequirementsStandard Therapy and DefinitionsBackgroundRevision History
  1. If documentation of current or continued standard therapy is not provided, the request is denied.
    2. Documentation Required

    Required documentation: baseline disease activity and LN biopsy/response

    Include baseline SLE disease activity assessment and other supporting documentation with the request: a validated functional assessment tool for SLE, or for lupus nephritis a renal biopsy within the prior 6 months to 2 years when baseline activity assessment is not present; for renewal of LN provide physician attestation of ≥50% reduction in proteinuria after 6 months.

    • Baseline assessment of SLE disease activity using a validated functional assessment tool is required for SLE (Criteria #3).
    • If SLE baseline assessment is not present, documentation of active lupus nephritis with a renal biopsy within the previous 6 months to 2 years is required (Criteria #4).
    • For LN renewal, documentation or physician attestation of at least a 50% reduction in proteinuria after 6 months of therapy is required (Renewal #4).
    Denial Risk

    Denial risks: prescriber, age, missing documentation, excluded therapies

    Requests are at risk of denial if prescriber specialty, age, or required documentation criteria are not met, or if excluded concurrent therapies or severe CNS lupus are present.

    • Deny if the prescription is not written by (or in consultation with) a rheumatologist or nephrologist (Criteria #2).
    • Deny if member age is ≤5 years for SLE (Criteria #5) or ≤18 years where age >18 is required for certain LN renewal criteria (Criteria #9/Renewal #4).
    • Deny if baseline SLE activity assessment or required renal biopsy documentation is missing (Criteria #3–#4).
    • Deny if the patient is currently on other biologic therapy or intravenous cyclophosphamide (Criteria #7), or if there is documentation of severe active CNS lupus (Criteria #8).
    • Deny renewal if documentation that the member will continue receiving standard therapy is not provided (Criteria #10).
    2023-06-17next_review_scheduledLatest

    Next review scheduled for 2023-06-17 per policy header metadata.